Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome

BACKGROUND: Rituximab (RTX) has recently been introduced as a second-line therapy for nephrotic syndrome in children. Studies show that RTX given during the nephrotic state may be less effective than treatment during a non-nephrotic state, possibly due to loss of RTX in the urine. CASE-DIAGNOSIS/TRE...

Descripción completa

Detalles Bibliográficos
Autores principales: Counsilman, Clare E., Jol–van der Zijde, Cornelia M., Stevens, Jasper, Cransberg, Karlien, Bredius, Robbert G. M., Sukhai, Ram N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483248/
https://www.ncbi.nlm.nih.gov/pubmed/26054711
http://dx.doi.org/10.1007/s00467-015-3120-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483248/
https://www.ncbi.nlm.nih.gov/pubmed/26054711
http://dx.doi.org/10.1007/s00467-015-3120-8

Ejemplares similares